CD28 signaling complexes are correlated with patient outcomes in anti-CD19 41BB-costimulation CAR T cell therapy

Background <p>Chimeric antigen receptor (CAR) T cells targeting CD19 achieve remarkable remissions in refractory B cell malignancies, yet deleterious side effects such as cytokine release syndrome (CRS) limit their broader application. Current preclinical assays on manufactured cell products do not predict human clinical function. We hypothesized that variability in the CAR proximal protein interaction networks that mediate CAR signal transduction…